 |
Oxford BioMedica
Development of VEGF Gene therapy for ALS
From April 2004, for the life of the patent |
 |
Galapagos
Generating a zebrafish model of osteoporosis
From November 2007 till October 2008 |
 |
Pfizer
Performing toxicity studies of anti-angiogenic agents in mouse models
From September 2006 till August 2007 |
 |
Johnson & Johnson
Assessing the clinical utility of anti-lymphangiogenesis compounds in zebrafish, xenopus and mice
From July 2006 till April 2007 |
 |
Philip Morris
Animal models to study PlGF as a therapy for myocardial and limb ischemia
From September 2004 till September 2007 |
 |
Schering
Evaluating the clinical utility of anti-lymphangiogenic compounds in the xenopus tadpole models.
From March 2006 till March 2007 |
|
Valorization 